EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling

Ankang Lu, Caojian Zuo, Yuhu He, Guilin Chen, Lingjuan Piao, Jian Zhang, Bing Xiao, Yujun Shen, Juan Tang, Deping Kong, Sara Alberti, Di Chen, Shenkai Zuo, Qianqian Zhang, Shuai Yan, Xiaochun Fei, Fei Yuan, Bin Zhou, Shengzhong Duan, Yu YuMichael Lazarus, Yunchao Su, Richard M. Breyer, Colin D. Funk, Ying Yu

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Pulmonary arterial hypertension (PAH) is commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD). Prostacyclin analogs are widely used in the management of PAH patients; however, clinical efficacy and long-term tolerability of some prostacyclin analogs may be compromised by concomitant activation of the E-prostanoid 3 (EP3) receptor. Here, we found that EP3 expression is upregulated in pulmonary arterial smooth muscle cells (PASMCs) and human distal pulmonary arteries (PAs) in response to hypoxia. Either pharmacological inhibition of EP3 or Ep3 deletion attenuated both hypoxia and monocrotaline-induced pulmonary hypertension and restrained extracellular matrix accumulation in PAs in rodent models. In a murine PAH model, Ep3 deletion in SMCs, but not endothelial cells, retarded PA medial thickness. Knockdown of EP3α and EP3β, but not EP3γ, isoforms diminished hypoxia-induced TGF-β1 activation. Expression of either EP3α or EP3β in EP3-deficient PASMCs restored TGF-β1 activation in response to hypoxia. EP3α/β activation in PASMCs increased RhoA-dependent membrane type 1 extracellular matrix metalloproteinase (MMP) translocation to the cell surface, subsequently activating pro'MMP-2 and promoting TGF-β1 signaling. Activation or disruption of EP3 did not influence PASMC proliferation. Together, our results indicate that EP3 activation facilitates hypoxia-induced vascular remodeling and pulmonary hypertension in mice and suggest EP3 inhibition as a potential therapeutic strategy for pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)1228-1242
Number of pages15
JournalJournal of Clinical Investigation
Volume125
Issue number3
DOIs
StatePublished - Mar 2 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling'. Together they form a unique fingerprint.

  • Cite this

    Lu, A., Zuo, C., He, Y., Chen, G., Piao, L., Zhang, J., Xiao, B., Shen, Y., Tang, J., Kong, D., Alberti, S., Chen, D., Zuo, S., Zhang, Q., Yan, S., Fei, X., Yuan, F., Zhou, B., Duan, S., ... Yu, Y. (2015). EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. Journal of Clinical Investigation, 125(3), 1228-1242. https://doi.org/10.1172/JCI77656